ArticleRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2026
Clinical impact of rapid antimicrobial susceptibility testing in patients with bacteremia due to gram-negative bacilli.
Article in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reducing time-to-result in bloodstream infections: comparative evaluation of VITEK® REVEAL™ and QuickMIC® for rapid phenotypic antimicrobial susceptibility testing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBacteremia and sepsis cause high morbidity and mortality worldwide. Rapid identification of bacteria and timely antimicrobial susceptibility testing (AST) can be crucial for patient survival. In the present study, we have compared isolates from patients whose ASTs were processed using MicroScan Walkaway Plus with those patients whose ASTs were processed more quickly using Vitek® Reveal™. We analyzed mortality, turnaround time to targeted therapy, and length of stay between the two groups, as well as other parameters. MATERIAL AND
methodsIn this prospective study, 120 patients with bacteremia caused by Gram-negative bacilli were included. In 60 patients, conventional AST (MicroScan WalkAway Plus) was performed, whereas in the other 60 patients, rapid AST (Vitek® Reveal™) was carried out.
resultsThe mortality rates were 13.3% and 38.3% for patients whose ASTs were performed with Vitek® Reveal™ and MicroScan WalkAway Plus, respectively (p=0.002). The average length of stay was 18 days per patient in the Vitek® Reveal™ group and 24.5 days for the MicroScan group (p=0.128). The average turnaround time was 12 hours per patient for Vitek® Reveal™ and 40 hours for MicroScan (p<0.001).
conclusionsThe introduction of rapid AST techniques such as Vitek® Reveal™ has allowed a shorter turnaround time for reports on AST than when using normal AST techniques. This allows most AST results to be available earlier in the Laboratory Information System, allowing physicians to initiate more quickly in establishing correct treatment. Finally, these actions have resulted in reduced mortality due to faster clinical decision-making in these critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.